2,871
Views
5
CrossRef citations to date
0
Altmetric
Letter

QTc prolongation and valproate toxicity

, , &
Page 193 | Received 31 Jan 2013, Accepted 08 Feb 2013, Published online: 11 Mar 2013

To the Editor:

We thank Ray and Skellett for highlighting the need for cardiac monitoring in patients presenting with valproic acid overdose.Citation1 Of note, they remarked on prolonged QTc in relation to high serum concentration of valproic acid that corrected as serum concentrations normalized. To our knowledge, a relationship between valproic acid overdose and QTc prolongation was previously reported, and the authors suggested that this effect might be due to valproic acid action on sodium channels.Citation2

However, it is also reported that severe valproic acid overdose, that is, in concentrations usually above 450 mg/L, can lead to hypocalcemia.Citation3,Citation4 Unfortunately, the authors Ray and Skellett did not report a serum calcium concentration for their case. We wonder whether the prolonged QTc observed might have been related to the underlying hypocalcemia. If the calcium concentrations were normal, other hypotheses could be formulated, such as reduced inward rectifying potassium currents in cardiac myocytes. Further studies on the electrophysiologic properties of valproic acid would help answer this question.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  • Ray S, Skellett S. Valproate toxicity in a child: two novel observations. Clin Toxicol (Phila) 2013; 51:60.
  • Kupferschimdt H, Seger D, Dawling S, Murray L, Meredith T. Multiple life-threatening metabolic complications in severe valproic acid overdose [abstract]. Clin Toxicol (Phila) 1998; 36:471.
  • Sztajnkrycer MD. Valproic acid toxicity: overview and management. Clin Toxicol (Phila) 2002; 40:789–801.
  • Beauchamp J, Olson K. Valproic acid overdoses: a retrospective study comparing serum drug levels and the incidence of adverse outcome [abstract]. Clin Toxicol (Phila) 1999; 37:637–638.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.